Related Experiment Video

Updated: Jul 16, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

Achievement of optimal combined lipid values in a managed care setting: is a new treatment paradigm needed?

Chaitanya A Sarawate1, Mark J Cziraky, Eric J Stanek

  • 1Health Core, Inc., Wilmington, Delaware 19801, USA. csarawate@healthcore.com

Clinical Therapeutics
|March 24, 2007
PubMed

Insights

Most patients did not achieve optimal lipid levels, even with therapy. Combination and targeted lipid therapies may improve outcomes for low-density lipoprotein cholesterol and triglycerides.

Area of Science:

  • Cardiovascular Medicine
  • Clinical Lipidology
  • Health Outcomes Research

Background:

  • Published guidelines recommend managing high-density lipoprotein cholesterol (HDL-C) and triglyceride (TG) levels after low-density lipoprotein cholesterol (LDL-C) goals are met.
  • Optimal management of combined lipid profiles remains a clinical challenge.

Purpose of the Study:

  • To evaluate the achievement of optimal combined lipid values (LDL-C, HDL-C, TGs) and associated therapies over time in a managed-care population.
  • To assess the impact of lipid-altering therapy on achieving optimal lipid profiles.

Main Methods:

  • Retrospective cohort analysis of 30,348 managed-care patients naive to lipid therapy.
  • Patients categorized as elevated-risk primary prevention (ERP) or coronary heart disease (CHD) and CHD risk equivalents (CHD-RE).
  • Assessment of optimal combined lipid values quarterly for up to 36 months, with multivariate logistic regression for therapy associations.

Main Results:

  • Only 22% of patients achieved optimal combined lipid values by 36 months; 78% did not.
  • Lipid therapy, mainly statin monotherapy, was prescribed to 30% of patients.
  • Lipid therapy was associated with achieving optimal LDL-C and TG values, but not HDL-C.

Conclusions:

  • A significant proportion of patients fail to reach optimal combined lipid levels despite therapy.
  • Combination lipid therapy and targeted approaches for specific lipid abnormalities may enhance the attainment of optimal lipid parameters.
  • Further research is needed to confirm causality and optimize lipid management strategies.
Abstract

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...